TG Therapeutics Reports Strong Q2 2025 Briumvi Sales, Raises Full-Year Guidance
TG Therapeutics announced impressive second-quarter 2025 results, driven by the continued strong performance of its relapsing multiple sclerosis (RMS) treatment, Briumvi. The company reported $138.8 million in US net revenue for Briumvi, a substantial 91% year-over-year increase and a 16% jump from the first quarter of 2025. Based on this momentum, TG Therapeutics has raised its full-year 2025 US net revenue guidance for Briumvi to $570-$575 million, up from its previous projection of $560 million. This positive performance raises a key question: Can Briumvi maintain this growth trajectory and solidify its position as a leading anti-CD20 therapy in the increasingly competitive RMS market?
The strong uptake of Briumvi reflects several factors, including a targeted launch strategy, growing physician confidence in the therapy, and positive patient experiences. The company’s efforts to differentiate Briumvi through its unique glycoengineered formulation and focus on convenient dosing regimens appear to be resonating with both healthcare providers and patients. This success comes at a crucial time for the RMS market, where treatment expectations are evolving rapidly, and patients are demanding more effective and convenient options. TG Therapeutics is actively pursuing innovations, such as subcutaneous formulations and combined day-one and day-fifteen IV dosing, aiming to further enhance convenience and potentially improve patient adherence.
The broader context of this success is the ongoing evolution of the anti-CD20 monoclonal antibody class in the treatment of MS. Briumvi’s performance adds to the growing body of evidence supporting the efficacy and safety of this class of therapies. However, the RMS treatment landscape remains competitive, with other established players and emerging therapies vying for market share. TG Therapeutics’ ability to differentiate Briumvi through clinical data demonstrating improved efficacy, safety, or convenience will be critical to maintaining its growth momentum.
Looking beyond the US market, TG Therapeutics is expanding Briumvi’s reach through partnerships with companies like Neuraxpharm, securing approvals in the European Union, United Kingdom, Switzerland, and Australia. This global expansion strategy will be crucial for long-term growth, but success hinges on navigating diverse regulatory landscapes and adapting commercial strategy to local market dynamics. Additionally, continued investment in research and development, including ongoing clinical trials for a subcutaneous Briumvi formulation, streamlined dosing regimens, and exploration of the drug’s potential in other autoimmune diseases, such as myasthenia gravis, is essential to maintain a competitive edge.
TG Therapeutics’ second-quarter results demonstrate the significant commercial potential of Briumvi in the RMS market. However, continued success will depend on several factors, including maintaining the current growth trajectory, successfully navigating increasing competition, expanding globally, and continuing to innovate in terms of formulation and dosing. Industry analysts and competitors alike will closely watch the company’s performance in the coming quarters, as it provides valuable insights into the evolving dynamics of the RMS treatment market and the potential of anti-CD20 therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
